타우메디칼 ㅣ Tau Medical Inc.

TAU-Medical

Our technology is a state-of-the-art treatment with a simple minimally invasive approach targeting specific areas or blood vessels within the heart valve and ventricular septum.

TAU-Medical

Our technology is a state-of-the-art treatment with a simple minimally invasive approach targeting specific areas or blood vessels within the heart valve and ventricular septum.

TAU-Medical

Our technology is a state-of-the-art treatment with a simple minimally invasive approach targeting specific areas or blood vessels within the heart valve and ventricular septum.

TAU-Medical

Our technology is a state-of-the-art treatment with a simple minimally invasive approach targeting specific areas or blood vessels within the heart valve and ventricular septum.

Pivot Bridge

The Pivot Bridge is a novel cardiac implant system
that treats the unmet medical challenge of tricuspid regurgitation (TR).
Through a simple minimally invasive and reversible procedure,
Pivot Bridge intends to be used as a TR ‘pre-hab’ therapy for the period
ranging from 4 days to 7 days prior to the scheduled tricuspid valve repair or tricuspid
valve replacement surgery, or medical treatment.

LV reshaping Loop

Beyond treating Mitral Valve Regurgitation,
Tau’s innovative device promotes LV reshaping for treatment of failing LV

Tricuspid Regurgitation Pivot-TR

LV Remodeling &
Mitral Regurgitation Mitral Loop Cerclage

Hypertrophic Cardiomyopathy Thru-Septal RF Ablation

Heart Arrhythmia Thru-Septal Pacing

Tricuspid
Regurgitation LV Remodeling &
Mitral Regurgitation

Hypertrophic
Cardiomyopathy Heart
Arrhythmia

Tricuspid Regurgitation Pivot-TR

LV Remodeling &
Mitral Regurgitation Mitral Loop Cerclage

Hypertrophic Cardiomyopathy Thru-Septal RF Ablation

Heart Arrhythmia Thru-Septal Pacing

3D Leaflet
TR Mitral Loop
Cercleage

Thru-Septal
RF Ablation Electrical
Pacing

The health of your heart
matters to Tau-Medical.
That’s why our team always
prioritizes excellence for technology.

Tau-Medical Inc.

We have been researching and developing state-of-the-art minimally invasive surgical methodologies for treating Tricuspid Valve Regurgitation (TR), Mitral Valve Regurgitation (MR), Hypertrophic Obstructive Cardiomyopathy (HOCM), and Heart arrhythmia. Our R&D centers and manufacturing facilities are located in Busan and Yangsan in Korea, and we are actively preparing for global clinical trials with top-tier cardiac clinical experts in the USA and Europe.

Office